AP3284A - Compositions for targeted delivery of SIRNA - Google Patents

Compositions for targeted delivery of SIRNA

Info

Publication number
AP3284A
AP3284A AP2012006453A AP2012006453A AP3284A AP 3284 A AP3284 A AP 3284A AP 2012006453 A AP2012006453 A AP 2012006453A AP 2012006453 A AP2012006453 A AP 2012006453A AP 3284 A AP3284 A AP 3284A
Authority
AP
ARIPO
Prior art keywords
sirna
compositions
targeted delivery
targeted
delivery
Prior art date
Application number
AP2012006453A
Other languages
English (en)
Other versions
AP2012006453A0 (en
Inventor
Peter Mohr
Eric A Kitas
David B Rozema
Original Assignee
Arrowhead Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Res Corp filed Critical Arrowhead Res Corp
Publication of AP2012006453A0 publication Critical patent/AP2012006453A0/xx
Application granted granted Critical
Publication of AP3284A publication Critical patent/AP3284A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2012006453A 2010-02-24 2011-02-18 Compositions for targeted delivery of SIRNA AP3284A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30749010P 2010-02-24 2010-02-24
PCT/EP2011/052393 WO2011104169A1 (en) 2010-02-24 2011-02-18 Compositions for targeted delivery of sirna

Publications (2)

Publication Number Publication Date
AP2012006453A0 AP2012006453A0 (en) 2012-08-31
AP3284A true AP3284A (en) 2015-05-31

Family

ID=43901424

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006453A AP3284A (en) 2010-02-24 2011-02-18 Compositions for targeted delivery of SIRNA

Country Status (25)

Country Link
US (4) US8313772B2 (de)
EP (2) EP2539451B1 (de)
JP (2) JP6137834B2 (de)
KR (1) KR101956623B1 (de)
CN (1) CN102869774B (de)
AP (1) AP3284A (de)
AU (1) AU2011219941C1 (de)
BR (1) BR112012021256A2 (de)
CA (1) CA2788600C (de)
DK (1) DK2539451T3 (de)
EA (1) EA024534B1 (de)
ES (1) ES2562817T3 (de)
HR (1) HRP20160093T1 (de)
HU (1) HUE026811T2 (de)
IL (1) IL221396A (de)
MX (1) MX2012009178A (de)
NZ (1) NZ601737A (de)
PL (1) PL2539451T3 (de)
PT (1) PT2539451E (de)
RS (1) RS54578B1 (de)
SG (1) SG183374A1 (de)
SI (1) SI2539451T1 (de)
SM (1) SMT201600079B (de)
WO (1) WO2011104169A1 (de)
ZA (1) ZA201205685B (de)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080281041A1 (en) * 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
KR101141544B1 (ko) 2009-03-13 2012-05-03 한국과학기술원 에스아이알엔에이 다중 접합체 및 이의 제조방법
JP2012520085A (ja) * 2009-03-13 2012-09-06 エーゲン、インコーポレイテッド 生物活性ｒｎａの送達のための組成物及び方法
PT2539451E (pt) * 2010-02-24 2016-03-28 Arrowhead Res Corp Composições para entrega de arnsi dirigida ao alvo
WO2011133876A2 (en) * 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
EP2600901B1 (de) 2010-08-06 2019-03-27 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
HRP20220796T1 (hr) 2010-10-01 2022-10-14 ModernaTX, Inc. Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
EP3192800A1 (de) * 2010-12-17 2017-07-19 Arrowhead Pharmaceuticals, Inc. Galactose-cluster-pharmakokinetischer modulator zur anzielung einer einheit für sirna
MX342609B (es) 2010-12-29 2016-10-06 Hoffmann La Roche Conjugados de molecula pequeña para suministro intracelular de acidos nucleicos.
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012173784A1 (en) 2011-06-17 2012-12-20 Arrowhead Madison Inc. Disubstituted maleic anhydrides with altered kinetics of ring closure
EP2807216A4 (de) * 2011-08-26 2015-10-28 Arrowhead Res Corp Poly(vinylester)polymere zur in-vivo-nukleinsäurefreisetzung
MX2014001971A (es) 2011-08-26 2014-03-31 Arrowhead Res Corp Polimeros de poli(vinilester) para suministro de acido nucleico in vivo.
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (de) 2011-10-03 2020-03-04 ModernaTX, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
WO2013096958A1 (en) * 2011-12-23 2013-06-27 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
WO2013102878A2 (en) 2012-01-05 2013-07-11 Department Of Biotechnology (Dbt) Fat1 gene in cancer and inflammation
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
EP2838544A4 (de) * 2012-04-18 2015-10-14 Arrowhead Res Corp Poly(acrylat)polymere für in-vivo-nukleinsäurefreisetzung
BR112014004528A2 (pt) * 2012-04-18 2019-09-24 Arrowhead Res Corp polímeros de poli(acrilato) para entrega de ácido nucleico in vivo
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
AR090906A1 (es) * 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y procedimientos para la administracion de oligonucleotidos
AR090905A1 (es) * 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
US10323279B2 (en) * 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US20140155295A1 (en) 2012-08-14 2014-06-05 10X Technologies, Inc. Capsule array devices and methods of use
US9801953B2 (en) 2012-10-15 2017-10-31 Emory University Nanoparticles carrying nucleic acid cassettes for expressing RNA
KR20150083920A (ko) 2012-11-15 2015-07-20 로슈 이노베이션 센터 코펜하겐 에이/에스 항 apob 안티센스 접합체 화합물
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
DK2958998T3 (en) * 2013-02-22 2018-04-16 Sirna Therapeutics Inc SHORT INTERFERATING NUCLEIC ACID (SINA) MOLECULES CONTAINING A 2'-INTERNUCLEOSIDE BOND
SG10201706960TA (en) 2013-02-28 2017-10-30 Arrowhead Res Corp Organic compositions to treat epas1-related diseases
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SG11201508925WA (en) 2013-05-01 2015-11-27 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
US9506030B2 (en) 2013-05-01 2016-11-29 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
RU2686080C2 (ru) 2013-05-01 2019-04-24 Ионис Фармасьютикалз, Инк. Композиции и способы
WO2015021092A1 (en) 2013-08-07 2015-02-12 Arrowhead Research Corporation Polyconjugates for delivery of rnai triggers to tumor cells in vivo
EP3052106A4 (de) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynukleotide zur codierung immunmodulierender polypeptide
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
UA124961C2 (uk) 2013-10-04 2021-12-22 Елнілем Фармасьютикалз, Інк. ДВОНИТКОВА РИБОНУКЛЕЇНОВА КИСЛОТА (dsRNA) ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ALAS1
WO2015061536A1 (en) 2013-10-25 2015-04-30 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
KR20160083876A (ko) * 2013-11-14 2016-07-12 로슈 이노베이션 센터 코펜하겐 에이/에스 ApoB 안티센스 접합체 화합물
EP3137476B1 (de) 2014-04-28 2019-10-09 Ionis Pharmaceuticals, Inc. Verbindungsmodifizierte oligomerverbindungen
EP3862362A3 (de) 2014-05-01 2021-10-27 Ionis Pharmaceuticals, Inc. Konjugate con antisens-oligonukleotides und deren verwendung zur modulation der pkk-expression
RS59182B1 (sr) 2014-05-01 2019-10-31 Ionis Pharmaceuticals Inc Kompozicije i postupci za modulaciju ekspresije faktora b komplementa
KR102356388B1 (ko) 2014-05-01 2022-01-26 아이오니스 파마수티컬즈, 인코포레이티드 안지오포이에틴-유사 3 발현을 조절하기 위한 조성물 및 방법
KR102149571B1 (ko) 2014-05-01 2020-08-31 아이오니스 파마수티컬즈, 인코포레이티드 성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
SG10201911695SA (en) 2014-05-14 2020-01-30 Targimmune Therapeutics Ag Improved polyethyleneimine polyethyleneglycol vectors
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2015188194A1 (en) * 2014-06-06 2015-12-10 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
US9487783B2 (en) 2014-08-07 2016-11-08 Regulus Therapeutics Inc. Targeting microRNAs for metabolic disorders
WO2016040748A1 (en) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
SG11201702877TA (en) 2014-10-10 2017-05-30 Hoffmann La Roche Galnac phosphoramidites, nucleic acid conjugates thereof and their use
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
JP6688292B2 (ja) * 2014-10-10 2020-04-28 ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 乳酸デヒドロゲナーゼ及びその薬剤の治療的阻害
EP3207138B1 (de) * 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
WO2016081808A1 (en) 2014-11-20 2016-05-26 The Regents Of The University Of California Compositions and methods related to hematologic recovery
WO2016138132A1 (en) * 2015-02-25 2016-09-01 The Trustees Of Columbia University In The City Of New York Dipeptidyl peptidase-iv(dpp4) inhibitors, methods and compositions for suppressing adipose tissue inflammation
US9803205B2 (en) * 2015-03-17 2017-10-31 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression of factor XII
CN114601845A (zh) 2015-05-29 2022-06-10 箭头药业股份有限公司 抑制Hif2α基因表达的组合物及方法
KR20180039621A (ko) 2015-06-15 2018-04-18 엠펙 엘에이, 엘엘씨 정의된 다중 접합체 올리고뉴클레오티드
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
US20180312845A1 (en) 2015-07-10 2018-11-01 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (dgat2)
MX369556B (es) * 2015-08-06 2019-11-12 Hoffmann La Roche Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
TW201723176A (zh) 2015-09-24 2017-07-01 Ｉｏｎｉｓ製藥公司 Ｋｒａｓ表現之調節劑
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
CA2999341A1 (en) 2015-11-06 2017-05-11 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
EP3371201A4 (de) 2015-11-06 2019-09-18 Ionis Pharmaceuticals, Inc. Konjugierte antisense-verbindungen zur verwendung in der therapie
MX2018005733A (es) * 2015-11-16 2018-08-09 Hoffmann La Roche Fosforamidita de agrupacion de n-acetilgalactosamina (galnac).
CA3005411C (en) 2015-11-16 2024-01-09 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
RU2754188C2 (ru) 2015-12-07 2021-08-30 Джензим Корпорейшн Способы и композиции для лечения ассоциированного с serpinc1 расстройства
US12110490B2 (en) 2015-12-18 2024-10-08 The Broad Institute, Inc. CRISPR enzymes and systems
CN108779463B (zh) 2016-02-02 2022-05-24 奥利克斯医药有限公司 使用靶向IL4Rα、TRPA1或F2RL1的RNA复合物治疗特应性皮炎和哮喘
CN113797348A (zh) * 2016-03-07 2021-12-17 箭头药业股份有限公司 用于治疗性化合物的靶向配体
US10407469B2 (en) 2016-04-01 2019-09-10 Northwestern University Programmable polypeptide and nucleic acid nanoparticles
MA45478A (fr) * 2016-04-11 2019-02-20 Arbutus Biopharma Corp Compositions de conjugués d'acides nucléiques ciblés
US11248019B2 (en) 2016-04-14 2022-02-15 Hoffmann-La Roche Inc. Trityl-mono-GalNAc compounds and their use
WO2017184786A1 (en) 2016-04-19 2017-10-26 The Broad Institute Inc. Cpf1 complexes with reduced indel activity
WO2017184768A1 (en) 2016-04-19 2017-10-26 The Broad Institute Inc. Novel crispr enzymes and systems
CN109689106B (zh) 2016-04-26 2023-01-24 微而广治疗有限公司 治疗虾类病毒感染的组合物和方法
KR102639586B1 (ko) 2016-06-06 2024-02-23 애로우헤드 파마슈티컬스 인코포레이티드 5'-시클로-포스포네이트 변형된 뉴클레오티드
IL264216B2 (en) 2016-07-15 2024-04-01 Ionis Pharmaceuticals Inc Compounds and Methods for Modulating SMN2
WO2018017814A1 (en) 2016-07-20 2018-01-25 President And Fellows Of Harvard College Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
JP6989521B2 (ja) 2016-09-02 2022-01-05 アローヘッド ファーマシューティカルズ インコーポレイテッド 標的化リガンド
US11202818B2 (en) 2016-09-14 2021-12-21 President And Fellows Of Harvard College Methods and compositions for modulating erythropoiesis
KR20190065341A (ko) 2016-10-06 2019-06-11 아이오니스 파마수티컬즈, 인코포레이티드 올리고머 화합물들의 접합 방법
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
WO2018112365A2 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
WO2018112363A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Methods of treating cancer using parabacteroides
WO2018112364A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018112360A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
AU2018208505B2 (en) 2017-01-10 2024-03-07 Arrowhead Pharmaceuticals, Inc. Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
WO2018136598A1 (en) 2017-01-18 2018-07-26 Evelo Biosciences, Inc. Methods of treating cancer
EP3570856A2 (de) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Verfahren zur behandlung von krebs
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
WO2018191278A2 (en) 2017-04-11 2018-10-18 Arbutus Biopharma Corporation Targeted compositions
WO2018215049A1 (en) * 2017-05-23 2018-11-29 F. Hoffmann-La Roche Ag Process for galnac oligonucleotide conjugates
WO2019010274A1 (en) 2017-07-06 2019-01-10 Arrowhead Pharmaceuticals, Inc. RNAI AGENTS OF INHIBITION OF ALPHA-ENAC GENE EXPRESSION AND METHODS OF USE
US11261447B2 (en) 2017-07-13 2022-03-01 Alnylam Pharmaceuticals, Inc. Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
TW201920648A (zh) 2017-08-29 2019-06-01 美商艾弗洛生物科技股份有限公司 使用布勞特氏(blautia)菌株治療癌症
TN2020000039A1 (en) 2017-09-11 2021-10-04 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
SG11201912188RA (en) 2017-09-14 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
KR102609396B1 (ko) 2017-10-13 2023-12-01 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Ldha의 발현을 억제하기 위한 방법 및 조성물
AU2018352379A1 (en) 2017-10-17 2020-06-04 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
JP2021504415A (ja) 2017-12-01 2021-02-15 スーチョウ リボ ライフ サイエンス カンパニー、リミテッドＳｕｚｈｏｕ Ｒｉｂｏ Ｌｉｆｅ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
AU2018377716A1 (en) 2017-12-01 2020-04-09 Suzhou Ribo Life Science Co., Ltd Nucleic acid, composition and conjugate containing same, and preparation method and use
CN110997917B (zh) 2017-12-01 2024-04-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
CA3087106A1 (en) 2017-12-29 2019-07-04 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
MX2020007369A (es) 2018-01-15 2020-10-28 Ionis Pharmaceuticals Inc Moduladores de la expresion de dnm2.
MX2020007915A (es) * 2018-01-29 2020-09-03 Hoffmann La Roche Proceso para la preparacion de conjugados de oligonucleotidos de n-acetilgalactosamina (galnac).
US11332733B2 (en) 2018-02-12 2022-05-17 lonis Pharmaceuticals, Inc. Modified compounds and uses thereof
WO2019169143A1 (en) 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using turicibacter sanguinis
WO2019169138A1 (en) 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using paraclostridium benzoelyticum
WO2019169168A1 (en) 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using agathobaculum
WO2019169160A1 (en) 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using ruminococcus gnavus
WO2019178057A1 (en) 2018-03-12 2019-09-19 Evelo Biosciences, Inc. Methods of treating cancer using burkholderia
KR20200140322A (ko) 2018-04-05 2020-12-15 사일런스 테라퓨틱스 게엠베하 안티센스 가닥의 5' 단부에 비닐포스포네이트를 갖는 siRNA
JP7353301B2 (ja) 2018-05-07 2023-09-29 アルニラム ファーマスーティカルズ インコーポレイテッド 肝臓外送達
CA3099698A1 (en) 2018-05-08 2019-11-14 Charles R. ALLERSON Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
JOP20200280A1 (ar) 2018-05-09 2020-11-05 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير الوراثي عن fxi
CN112424356A (zh) 2018-07-20 2021-02-26 莱古路斯治疗法股份有限公司 用于经口递送寡核苷酸的方法
US20210292768A1 (en) 2018-08-08 2021-09-23 Arcturus Therapeutics, Inc. Compositions and agents against nonalcoholic steatohepatitis
JP2021533800A (ja) 2018-08-21 2021-12-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. 核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用
US11273137B2 (en) 2018-09-04 2022-03-15 Board Of Trustees Of Michigan State University Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene
TW202423454A (zh) 2018-09-19 2024-06-16 美商Ionis製藥公司 Pnpla3表現之調節劑
EP3862024A4 (de) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. Sirna-konjugat, verfahren zu seiner herstellung und seine verwendung
CN112423795A (zh) * 2018-12-28 2021-02-26 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
KR20210110839A (ko) * 2018-12-28 2021-09-09 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 핵산을 함유하는 조성물 및 접합체, 이의 제조 방법 및 용도
KR20210130736A (ko) 2019-02-07 2021-11-01 애로우헤드 파마슈티컬스 인코포레이티드 B형 간염 바이러스 감염에 대한 RNAi 작용제
IL295153A (en) 2019-03-12 2022-09-01 Harvard College Methods and preparations for the treatment of cancer
AU2020259482A1 (en) 2019-04-18 2021-10-14 Janssen Pharmaceuticals, Inc. Combination therapy for treating Hepatitis B Virus infection
TW202106294A (zh) 2019-04-18 2021-02-16 美商健生醫藥公司 用於治療ｂ型肝炎病毒感染的組合療法（一）
US20220226269A1 (en) 2019-06-12 2022-07-21 President And Fellows Of Harvard College Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
CA3143679A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
EP3986562A1 (de) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Kombination von hepatitis-b-virus(hbv)-impfstoffen und auf hbv abzielender rnai
CN110218728A (zh) * 2019-06-28 2019-09-10 厦门甘宝利生物医药有限公司 一种新化合物及其应用
CA3144467A1 (en) * 2019-07-30 2021-02-04 Jonathan Miles Brown Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
WO2021022110A1 (en) 2019-08-01 2021-02-04 Evelo Biosciences, Inc. Inducing immune effects using bacteria of the genus bifidobacterium
EP4045062A1 (de) 2019-10-14 2022-08-24 Astrazeneca AB Modulatoren der pnpla3-expression
EP4086275A4 (de) * 2019-12-31 2024-04-17 Xiamen University Multimerisationsabgabesystem zur intrazellulären abgabe von molekülen
WO2021141368A2 (ko) 2020-01-06 2021-07-15 주식회사 시선테라퓨틱스 세포 투과성 핵산 복합체를 유효성분으로 함유하는 황반변성의 예방 또는 치료용 조성물
MX2022010602A (es) 2020-02-28 2022-09-09 Ionis Pharmaceuticals Inc Compuestos y metodos para modular smn2.
KR20230004456A (ko) 2020-03-04 2023-01-06 리제너론 파아마슈티컬스, 인크. 면역 요법에 대한 종양 세포의 감작화를 위한 방법 및 조성물
TW202146011A (zh) 2020-03-05 2021-12-16 美商詹森藥物公司 治療b型肝炎病毒感染之組合療法
JP2023519246A (ja) 2020-03-26 2023-05-10 アローヘッド ファーマシューティカルズ インコーポレイテッド ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法
EP4157264A4 (de) 2020-05-27 2024-06-19 The Regents of the University of California Zusammensetzungen und verfahren zur transdifferenzierung von zellen
JP2023531682A (ja) 2020-06-22 2023-07-25 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｄ型肝炎ウイルス感染の処置のための組成物および方法
WO2022056266A2 (en) 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
AU2021342158A1 (en) 2020-09-11 2023-04-13 Arrowhead Pharmaceuticals, Inc. Lipid conjugates for the delivery of therapeutic agents
MX2023002939A (es) 2020-09-11 2023-04-11 Arrowhead Pharmaceuticals Inc Plataformas para el transporte de farmacos hacia el musculo esqueletico y metodos de uso.
WO2022056454A2 (en) 2020-09-14 2022-03-17 President And Fellows Of Harvard College Methods and compositions for treating hpv-positive cancers
EP4213947A2 (de) 2020-09-16 2023-07-26 President and Fellows of Harvard College Verfahren zur behandlung einer person mit fehlgeschlagener anti-pd-1/anti-pd-l1-therapie
US11447521B2 (en) 2020-11-18 2022-09-20 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
CN114767704B (zh) * 2021-01-21 2024-06-14 圣诺制药公司 一种能够靶向乙型肝炎病毒的药物构造及药物组合物
US11549112B1 (en) 2021-06-21 2023-01-10 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
CA3224600A1 (en) 2021-07-09 2023-01-12 Glaxosmithkline Intellectual Property (No.3) Limited Use of oligonucleotides for individuals with renal impairment
CA3233755A1 (en) 2021-10-01 2023-04-06 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
CN118679256A (zh) 2021-11-09 2024-09-20 微而广治疗有限公司 用于水产养殖的组合物
WO2023150181A1 (en) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Methods and compositions for treating cancer
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
US11912997B2 (en) 2022-06-15 2024-02-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use
WO2024151942A2 (en) 2023-01-13 2024-07-18 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239204A1 (en) * 1994-09-28 2005-10-27 Wyeth Multifunctional molecular complexes for gene transfer to cells
WO2008022309A2 (en) * 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
US20080281041A1 (en) * 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
WO1993019768A1 (en) 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
JP2690276B2 (ja) 1995-01-10 1997-12-10 科学技術振興事業団 静電結合型高分子ミセル薬物担体とその薬剤
JP2000501414A (ja) 1995-11-22 2000-02-08 ザ・ジョンズ・ホプキンス・ユニバーシティー 生体分子の細胞取り込みを高めるリガンド
US20020165183A1 (en) 1999-11-29 2002-11-07 Hans Herweijer Methods for genetic immunization
US8217015B2 (en) 2003-04-04 2012-07-10 Arrowhead Madison Inc. Endosomolytic polymers
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US20050119470A1 (en) 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US6020457A (en) 1996-09-30 2000-02-01 Dendritech Inc. Disulfide-containing dendritic polymers
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
DE19652586A1 (de) 1996-12-17 1998-06-18 Biotechnolog Forschung Gmbh Dhc-Peptid und Mittel
ATE321882T1 (de) 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
US20050112470A1 (en) * 1998-06-26 2005-05-26 Johnson Controls Technology Company Alloy for battery grids
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
EP1102785B1 (de) 1999-06-07 2013-02-13 Arrowhead Research Corporation Zusammensetzungen zum drogentransport mit ph sensitiven molekülen
US7442764B2 (en) 1999-06-07 2008-10-28 Mirns Bio Corporation Reversible modification of amine-containing compounds
US7019113B2 (en) 1999-06-07 2006-03-28 Mirus Bio Corporation Reversible modification of membrane interaction
US8211468B2 (en) 1999-06-07 2012-07-03 Arrowhead Madison Inc. Endosomolytic polymers
US20040072785A1 (en) 1999-11-23 2004-04-15 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US7098030B2 (en) 1999-12-31 2006-08-29 Mirus Bio Corporation Polyampholytes for delivering polyions to a cell
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
JP2002122707A (ja) 2000-10-13 2002-04-26 Canon Inc 非球面マイクロ構造体、及びその作製方法
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2004033620A2 (en) 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US7176303B2 (en) 2003-11-06 2007-02-13 Isis Pharmaceuticals, Inc. Modulation of STAT5 expression
DE60328383D1 (de) 2002-05-24 2009-08-27 Mirus Bio Corp Zusammensetzungen zur zuführung von nukleinsäuren an zellen
WO2004028471A2 (en) 2002-09-28 2004-04-08 Massachusetts Institute Of Technology Influenza therapeutic
EP1585756B1 (de) 2002-11-26 2010-04-21 University of Massachusetts Verabreichung von sirnas
US7682626B2 (en) 2003-02-07 2010-03-23 Roche Madison Inc. Polyvinylethers for delivery of polynucleotides to mammalian cells
US7816337B2 (en) 2003-02-18 2010-10-19 Roche Madison Inc. Reversible attachment of a membrane active polymer to a polynucleotide
US8324365B2 (en) 2003-04-03 2012-12-04 Korea Advanced Institute Of Science And Technology Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
US8454566B2 (en) 2003-07-10 2013-06-04 Medtronic Minimed, Inc. Methods and compositions for the inhibition of biofilms on medical devices
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20060008907A1 (en) 2004-06-09 2006-01-12 The Curators Of The University Of Missouri Control of gene expression via light activated RNA interference
WO2006053430A1 (en) 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
US20060166234A1 (en) 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
EP1841867A1 (de) 2005-01-24 2007-10-10 Avaris AB Komplex mit sirna, shrna oder antisense-molekül und funktionselement für verbesserte spezifität und zuführung
EP1907444B1 (de) 2005-04-01 2009-08-19 Intezyne Technologies Incorporated Polymermicellen für die arzneistoffzufuhr
US9139850B2 (en) 2005-05-19 2015-09-22 L'oreal Vectorization of dsRNA by cationic particles and topical use
JP2007112768A (ja) * 2005-10-24 2007-05-10 Kyoto Univ 肝指向性リポソーム組成物
US8017109B2 (en) 2006-08-18 2011-09-13 Roche Madison Inc. Endosomolytic poly(acrylate) polymers
PT2539451E (pt) * 2010-02-24 2016-03-28 Arrowhead Res Corp Composições para entrega de arnsi dirigida ao alvo

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239204A1 (en) * 1994-09-28 2005-10-27 Wyeth Multifunctional molecular complexes for gene transfer to cells
US20080281041A1 (en) * 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
WO2008022309A2 (en) * 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
US20080152661A1 (en) * 2006-08-18 2008-06-26 Rozema David B Polyconjugates for In Vivo Delivery of Polynucleotides

Also Published As

Publication number Publication date
US8313772B2 (en) 2012-11-20
US10316316B2 (en) 2019-06-11
EP3023495B1 (de) 2019-05-08
HUE026811T2 (en) 2016-07-28
JP6137834B2 (ja) 2017-05-31
KR20130012112A (ko) 2013-02-01
WO2011104169A1 (en) 2011-09-01
EP2539451B1 (de) 2016-01-06
RS54578B1 (en) 2016-06-30
US20150202298A1 (en) 2015-07-23
AU2011219941A1 (en) 2012-08-16
EP2539451A1 (de) 2013-01-02
NZ601737A (en) 2013-06-28
EA201290602A1 (ru) 2013-04-30
CA2788600A1 (en) 2011-09-01
US20160222384A1 (en) 2016-08-04
EA024534B1 (ru) 2016-09-30
JP2016074671A (ja) 2016-05-12
AP2012006453A0 (en) 2012-08-31
KR101956623B1 (ko) 2019-03-12
PT2539451E (pt) 2016-03-28
JP2013520460A (ja) 2013-06-06
SI2539451T1 (sl) 2016-04-29
PL2539451T3 (pl) 2016-08-31
ZA201205685B (en) 2013-09-25
MX2012009178A (es) 2012-11-30
CA2788600C (en) 2019-12-03
AU2011219941B2 (en) 2014-10-23
CN102869774B (zh) 2018-02-09
JP6290848B2 (ja) 2018-03-07
US20170204408A9 (en) 2017-07-20
US9011919B2 (en) 2015-04-21
AU2011219941C1 (en) 2015-05-07
US9345775B2 (en) 2016-05-24
US20110207799A1 (en) 2011-08-25
HRP20160093T1 (hr) 2016-02-26
IL221396A (en) 2016-11-30
IL221396A0 (en) 2012-10-31
US20130245091A1 (en) 2013-09-19
DK2539451T3 (da) 2016-04-04
EP3023495A1 (de) 2016-05-25
SMT201600079B (it) 2016-04-29
CN102869774A (zh) 2013-01-09
ES2562817T3 (es) 2016-03-08
BR112012021256A2 (pt) 2018-03-06
SG183374A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
AP3284A (en) Compositions for targeted delivery of SIRNA
HK1246715A1 (zh) 用於靶向熱調節的組合物和方法
HRP20180924T1 (hr) Sastavi za transdermalnu administraciju aktivnih sastojaka
GB201121070D0 (en) composition for delivery of biotherapeutics
HUE059110T2 (hu) Módosított MRNS készítmények
HUE042850T2 (hu) Készítmények hatóanyag szállításra
EP2790736A4 (de) In-vivo-verabreichung von oligonucleotiden
ZA201304687B (en) Biodegradable drug delivery compositions
EP2470019A4 (de) Zusammensetzungen zur verabreichung nichtlöslicher mittel
EP2544768A4 (de) Mittel zur verabreichung von krebsheilmitteln mit verbesserter ladung
EP2776056A4 (de) Neue zusammensetzung zur genfreisetzung
PT2768864T (pt) Composições com concentrações aumentadas de carboximetilcelulose
ZA201003844B (en) Delivery of functional compounds
ZA201402166B (en) Compositions of efavirenz
EP2408462A4 (de) Gezielte verabreichung chemotherapeutischer mittel
GB201015091D0 (en) Enhanced delivery of sirna
GB201014935D0 (en) Enhanced delivery of siRNA
GB201014931D0 (en) Enhanced delivery of nucleic
IL226237A0 (en) Pharmaceutical preparations for administration through the skin